I met Sammie last September when she had Stage2b breast cancer with a BRCA gene mutation.
After chemotherapy, radiation, a double mastectomy and an oophorectomy her cancer had spread to her lungs -5 months later! Her doctor put her on Lynparza and she is doing GREAT and wanted me to share how grateful she is for companies like AstraZeneca who are helping give us all hope that we can beat this disease. Samantha Sinkler is my web content/social media director and together we have an unstoppable passion to create a global movement for the support and education for breast cancer! Come join us and celebrate all the incredible new advancements being made in the pharmaceutical industry.
PARP Inhibitors Slow Spread of Inherited Breast Cancer Caused by BRCA Mutations.
PARP Inhibitors improve outcomes in BRCA mutated breast cancer. ASCO 2021 trial update suggests benefit for early and late stage cancers
The US Food and Drug Administration (FDA) approved Lynparza (olaparib) for treatment of metastatic breast cancer in patients who carry the specific inherited BRCA mutation and data released at the 2021 American Society of Clinical Oncolgy Annual Meetings suggests Lynparza may benefit women with earlier stage breast cancers as well. Lynparza belongs to a class of precision cancer medicines known as “PARP” inhibitors. Lynparza and other PARP inhibitors were developed to treat BRCA mutated ovarian cancer and are increasingly used to treat other BRCA mutated cancers including breast, prostate and pancreatic cancer.